Article and Video CATEGORIES
The current standard of care for SCLC shows limited results with high toxicities. Drs. Soria, Gandhi, and West discuss new ASCO 2015 data that show promise for a subset of patients with PD-L1 expression on Keytruda (pembrolizumab) or Opdivo (nivolumab).
[powerpress]
Please feel free to offer comments and raise questions in our Discussion Forums.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi Stan,
It's so good to hear you and yours are doing well and that you were able to spend time with both families for Thanksgiving. I know it meant a...
Hi Stan! It is good to hear from you -- I am so very happy you are doing well. I agree with Janine that family and friends - our chosen family...
Recent Comments
I understand…